Sha Wang

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Perceptive is a seed and pre-seed venture firm investing in AI-first companies across a variety of sectors. We find, fund, and support world-class founders ushering in the AI revolution that is transforming human society. Our portfolio companies span consumer, B2B SaaS, and robotics.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

Owl Ventures is the largest venture capital firm in the world focused on the education technology market with over $2 billion in assets under management. The Silicon Valley-based firm invests in the worlds leading education technology companies across the education spectrum encompassing PreK-12, higher education and future of work (career mobility/professional learning). Owl Ventures has deep domain expertise and leverages a global network of Limited Partners, investors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies.

We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.

Established on October 9, 2019, Vitalbridge is committed to discovering Chinas most dynamic entrepreneurs of vitality in the next decade. Jointly, Vitalbridge grows with them to create long-term value. As a new generation of thesis-driven venture capital fund in China, we are entrusted with domestic and overseas long-term funds, which mainly include top institutional investors and industrial capital such as industry leaders, Internet entrepreneurs, founders of domestic and overseas listed companies, overseas FoFs and family offices. We appreciate and worship Vitality. Its our vision and mission to be Bridge of Vitality and to explore the infinite explosive power. Together with the entrepreneurial experience, industrial insights and resources, and long-term PE capital in the Vitalbridge eco-system, we are committed to the long-term development of our enterprises. China is transitioning from scale economies to quality economies, and Vitalbridge approaches this shift from “demographic structure" and "technological innovation" perspectives. Vitalbridge focuses on scientific and technological services in AI, robotics and technology services. Aiming to support the upgrade of “New Service” enabled by technologies, we invest in early and growth stage startups with single investment from US$ 3 million to 30 million.

Sherpa Capital, with over 14 years of experience, is the leading private equity firm in Iberia. Its investment strategy, Operational Value, focuses on mid-sized companies with strategic and operational challenges. It manages over 350 million euros, standing out for its model of sustainable value creation through business improvements. Its team of 40 experts with deep operational knowledge works closely with portfolio companies, employing a unique methodology that allows for the development of plans tailored to different challenges. This approach ensures the scalability and long-term evolution of businesses, positioning Sherpa as a benchmark in business transformation and value creation.

Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine. ​ We invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health. ​ Our strategic relationship with Illumina provides us access to the expertise and vision of the worlds leading genomics solutions provider. Our team members have decades of entrepreneurial experience in genomics and a passion for improving human health.

Boyu Capital is a China-focused investment firm.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Perceptive is a seed and pre-seed venture firm investing in AI-first companies across a variety of sectors. We find, fund, and support world-class founders ushering in the AI revolution that is transforming human society. Our portfolio companies span consumer, B2B SaaS, and robotics.

Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data.

New Markets Venture Partners is a leading early- and growth-stage venture capital firm that invests in and helps build transformative education, information technology and business services companies that drive superior financial returns through high customer ROI. New Markets is led by a veteran investment team with a 25-year track record of outperformance. As one of the leading education venture firms in the U.S., we maintain deep relationships with states, districts, universities, and other centers of workforce innovation that allow us to provide exceptional value to our portfolio companies. New Markets adds value to our portfolio companies before, during and after the investment process.

Owl Ventures is the largest venture capital firm in the world focused on the education technology market with over $2 billion in assets under management. The Silicon Valley-based firm invests in the worlds leading education technology companies across the education spectrum encompassing PreK-12, higher education and future of work (career mobility/professional learning). Owl Ventures has deep domain expertise and leverages a global network of Limited Partners, investors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies.